Steve Glover, Co-Founder, Chairman, and CEO of ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company discusses the work the company is doing to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. They are well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor (IC 100), and in kidney disease with a novel phase 2a-ready cholesterol efflux mediator (VAR 200). Lead products in each therapeutic area offer a “pipeline within a product,” with the potential for numerous indications. Currently, there is very little research being done in the renal space.
Steve Glover, Co-Founder, Chairman, and CEO of ZyVersa Therapeutics.
Mr. Glover has over 32 years of business experience in biopharmaceuticals and life sciences. Mr. Glover was formerly the Co-Founder of Coherus Biosciences where he was focused on business strategy, partnerships, product development efforts, and capitalization of the company.
Prior to Coherus, he was the President of Insmed Therapeutic Proteins as well as Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As Chief Business Officer he led Insmed’s strategic review process which resulted in the merger of Insmed and Transave.
Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation.
At Andrx Mr. Glover was responsible for the strategy and operation of the Andrx Labs which developed and marketed products in metabolic diseases and Men’s Health, and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health.
Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. His transaction experience covers over 25 transactions totaling over $10 billion, and he serves on the Boards of PDS Biotechnology and Asclepius Lifesciences.